Suppr超能文献

尽管常规凝血测试延长,肝移植患者的凝血酶生成仍处于正常至增加状态。

Normal to increased thrombin generation in patients undergoing liver transplantation despite prolonged conventional coagulation tests.

机构信息

Surgical Research Laboratory, Department of Surgery, University Medical Center Groningen, University of Groningen, Groningen, The Netherlands.

出版信息

J Hepatol. 2010 Mar;52(3):355-61. doi: 10.1016/j.jhep.2009.12.001. Epub 2009 Dec 24.

Abstract

BACKGROUND & AIMS: Patients with liver disease often show substantial changes in their hemostatic system, which may aggravate further during liver transplantation. Recently, thrombin generation in patients with stable disease was shown to be indistinguishable from controls provided thrombomodulin, the natural activator of the anticoagulant protein C system, was added to the plasma. These results indicated that the hemostatic balance is preserved in patients with liver disease, despite conventional coagulation tests suggest otherwise.

METHODS

Here we examined thrombin generation profiles in serial plasma samples taken from ten consecutive patients undergoing liver transplantation.

RESULTS

At all time points, the endogenous thrombin potential (ETP) was slightly lower compared to healthy volunteers, despite substantially prolonged PT and APTT values. However, when thrombin generation was tested in the presence of thrombomodulin, the ETP was equal to or even higher than that in healthy subjects. In fact, thrombin generation was hardly affected by thrombomodulin, while thrombin generation in healthy subjects decreased profoundly upon the addition of thrombomodulin. In patients undergoing liver transplantation, efficient thrombin generation in the presence of thrombomodulin may be explained by decreased levels of protein C, S, and antithrombin, and by elevated levels of FVIII.

CONCLUSIONS

Thrombin generation in patients undergoing liver transplantation is equal or even superior to thrombin generation in healthy volunteers when tested in the presence of exogenous thrombomodulin. These results support the recently advocated restrictive use of plasma during liver transplantation and warrants further study of the prophylactic use of anticoagulants to reduce thromboembolic complications after transplantation.

摘要

背景与目的

患有肝脏疾病的患者其止血系统通常会发生显著变化,而这种变化在肝移植期间可能会进一步加重。最近的研究表明,对于病情稳定的患者,当向血浆中添加血栓调节蛋白(抗凝蛋白 C 系统的天然激活剂)时,其凝血酶生成与对照组无法区分。这些结果表明,尽管常规凝血检测表明并非如此,但肝脏疾病患者的止血平衡得以维持。

方法

本研究中,我们连续检测了 10 例接受肝移植手术的患者的多个血浆样本中的凝血酶生成谱。

结果

与健康志愿者相比,所有时间点的内源性凝血酶潜能(ETP)均略低,尽管凝血酶原时间(PT)和活化部分凝血活酶时间(APTT)明显延长。但是,当在存在血栓调节蛋白的情况下检测凝血酶生成时,ETP 与健康受试者相等甚至更高。实际上,血栓调节蛋白几乎不会影响凝血酶生成,而健康受试者的凝血酶生成在添加血栓调节蛋白后会显著降低。在接受肝移植的患者中,在外源血栓调节蛋白存在的情况下,有效凝血酶生成可能归因于蛋白 C、S 和抗凝血酶水平降低,以及 FVIII 水平升高。

结论

当在存在外源性血栓调节蛋白的情况下检测时,接受肝移植手术的患者的凝血酶生成与健康志愿者的凝血酶生成相等或甚至更高。这些结果支持最近提出的在肝移植期间限制使用血浆的建议,并需要进一步研究预防性使用抗凝剂以减少移植后的血栓栓塞并发症。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验